MiNK Therapeutics, Inc.INKTNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank9
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P9
Near historical low
vs 3Y Ago
-8.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q3 2025-37.84%
Q2 202545.75%
Q1 2025-10.25%
Q4 2024160.06%
Q3 2024-70.62%
Q2 2024-27.83%
Q1 2024-23.00%
Q4 2023-3.40%
Q3 2023-24.81%
Q2 20238.70%
Q1 2023-27.85%
Q4 2022-5.49%
Q3 20224.66%
Q2 202211.35%
Q1 202233.57%
Q4 202118.50%
Q3 2021-6.99%
Q2 202115.72%
Q1 2021293.20%
Q4 2020-68.54%
Q3 2020-19.45%
Q2 2020-0.00%
Q1 20200.00%